ClinicalTrials.gg
CompletedNCT03406949Updated May 19, 2022

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

A Phase 1 interventional study of obrindatamab and retifanlimab in Advanced Solid Tumors, sponsored by MacroGenics. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-19.

Sponsored by MacroGenics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of obrindatamab administered in combination with retifanlimab in patients with B7-H3- expressing tumors.

Read the detailed description

This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, PK, pharmacodynamics, immunogenicity, and preliminary antitumor activity of the combination of obrindatamab and retifanlimab, each of which is administered by IV infusion. The study consists of a Dose Escalation Phase to determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) (if no MTD is defined) of the combination, followed by a Cohort Expansion Phase to further define the safety and initial antitumor activity of the combination with the doses established in the Dose Escalation Phase. Patients with B7-H3-expressing unresectable, locally advanced, or metastatic solid tumors of any histology will be enrolled in the Dose Escalation Phase. Following the establishment of an MTD, additional patients with specific tumor types will enroll in the Cohort Expansion Phase.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

MacroGenics is the lead sponsor of 42 studies on the registry; 4 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 11 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven, unresectable locally advanced or solid tumors of any histology that test positive for B7-H3 expression on tumor cells or vasculature for whom no approved therapy with demonstrated clinical benefit is available. For all tumor types, the requirement for previous systemic therapy may be waived if a patient was intolerant of or refused standard therapy
  • (ECOG) performance status of 0 or 1
  • ≥ 12 weeks
  • , with the exception of prostate cancer
  • Tissue specimen available for B7-H3 and expression testing
  • Acceptable laboratory parameters
  • Patients who have previously received an immune checkpoint inhibitor (e.g., anti- PD-L1, anti-PD-1, anti-CTLA-4) prior to enrollment must have toxicities related to the checkpoint inhibitor resolved to ≤ Grade 1 or baseline (prior to the checkpoint inhibitor) to be eligible for enrollment. Patients who experienced previous hypothyroidism toxicity on a checkpoint inhibitor are eligible to enter study regardless of Grade resolution as long as the patient is well controlled on thyroid replacement hormones.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of prior central nervous system (CNS) must have been treated, must be asymptomatic, and must not have any of the following at the time of enrollment:

    1. No concurrent treatment for the CNS disease (e.g. surgery, radiation, >10 mg prednisone/day or equivalent)
    2. No progression of on MRI or CT for at least 14 days after last day of prior therapy for the CNS metastases
    3. No concurrent or cord compression
  • Patients with any history of known or suspected disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing
  • Treatment with any, therapy within the 4 weeks prior to the initiation of study drug administration
  • Treatment with any systemic chemotherapy within 3 weeks
  • Treatment with radiation therapy within 2 weeks
  • History of allogeneic bone marrow, stem-cell, or solid organ transplant
  • Treatment with systemic corticosteroids (> 10 mg per day prednisone or equivalent) or other immune suppressive drugs within 2 weeks
  • cardiovascular or pulmonary disease
  • Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug.
  • Known history of positive testing for or history of acquired immune deficiency syndrome
  • Known history of or infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    obrindatamab + retifanlimab

    B7-H3 x CD3 DART protein + anti-PD-1 antibody

    Biological: obrindatamab · Biological: retifanlimab

Interventions

  • Biologicalobrindatamab

    B7-H3 x CD3 DART protein

    Also known as: MGD009

  • Biologicalretifanlimab

    anti-PD-1 antibody

    Also known as: INCMGA00012, MGA012

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03

    Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.

    Time frame: 30 months

  2. MTD/MAD

    Maximum Tolerated or Administrated Dose of obrindatamab and retifanlimab

    Time frame: 18 months

Secondary outcomes

  1. AUC

    Area Under the Plasma Concentration versus Time Curve of obrindatamab and retifanlimab

    Time frame: 30 months

  2. Cmax

    Maximum Plasma Concentration of obrindatamab and retifanlimab

    Time frame: 30 months

  3. Tmax

    Time to reach maximum (peak) plasma concentration of obrindatamab and retifanlimab

    Time frame: 30 months

  4. Ctrough

    Trough plasma concentration of obrindatamab and retifanlimab

    Time frame: 30 months

  5. CL

    Total body clearance of the drug from plasma of obrindatamab and retifanlimab

    Time frame: 30 months

  6. Vss

    Apparent volume of distribution at steady state of obrindatamab and retifanlimab

    Time frame: 30 months

  7. t1/2

    Terminal half life of obrindatamab and retifanlimab

    Time frame: 30 months

  8. ADA

    Percent of patients with anti-drug antibody to obrindatamab and retifanlimab

    Time frame: 30 months

  9. Anti-tumor activity

    Conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related response criteria (irRECIST)

    Time frame: 30 months

07

Study locations

10 sites
  • City of Hope Medical Center
    Duarte, California 91010, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02214, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • START (South Texas Accelerated Research Therapeutics) - Midwest
    Grand Rapids, Michigan 49546, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Mary Crowley Cancer Center
    Dallas, Texas 75251, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Apr 2022, 50 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Jan 23, 2018
StartActual
Feb 27, 2018
Primary completionActual
Apr 27, 2022
CompletionActual
Apr 27, 2022
Last update
May 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03406949
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Feb 27, 2018
Primary completion
Apr 27, 2022
Completion
Apr 27, 2022
Last update
May 19, 2022

Study contacts

Stephen L Eck, M.D.
study director · MacroGenics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retifanlimab

Start the discussion